Vistagen Cuts 31% of Workforce to Preserve Cash for Fasedienol Phase 3
VTGN is trading near its 52-week low of $0.165 (3.7% above the low).
Summary
Vistagen is cutting about 31% of its workforce, taking roughly $1.0 million in severance charges to save about $3.2 million a year, with remaining staff focused on fasedienol's Phase 3 program.
Key Events · Executive and Board Changes · VTGN
-
31% Workforce Reduction Implemented
A Board-approved reduction in workforce of approximately 31% was implemented October 26, 2026, retaining core clinical, regulatory, technical and corporate staff for U.S. registration-directed Phase 3 development of fasedienol.
-
$1.0M Charge, $3.2M Annual Savings
The company estimates roughly $1.0 million in severance and termination costs against expected annual savings of approximately $3.2 million in salary and benefits.
-
Cash Pressure Behind the Cut
The restructuring follows previously disclosed going-concern doubt and a $13.0M quarterly net loss with cash runway uncertain beyond twelve months, so the savings extend runway rather than close the funding gap.
-
Nasdaq Compliance Deadline February 2027
Nasdaq granted an extension until February 2027 to regain compliance, a deadline that now sits alongside the reduced cost base.
Analysis · VTGN · Life Sciences
Vistagen is cutting roughly 31% of its staff, a restructuring that costs about $1.0 million in severance but saves roughly $3.2 million a year in salary and benefits. For a company that previously disclosed going-concern doubt and cash that would not fund a full year, that is a meaningful extension of runway, and it concentrates the remaining organization on U.S. registration-directed Phase 3 work for fasedienol. The trade-off is real: fewer people means less capacity to run additional programs, and the savings are modest against a quarterly loss of $13.0M reported in the August 10-Q, so this buys time rather than solving the funding gap. Nasdaq's February 2027 compliance deadline remains the nearer constraint.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VTGN was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.17 to $5.14. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.